New Zealand’s a2 Milk Company has signalled its intention to branch out from infant formula into a broader range of dairy-based nutritional products – with the burgeoning China market very much in its sights.
Sales at Chinese infant nutrition firm Biostime dropped by 14% in the first half of 2016 to RMB1.46bn (US$220m), with the Biostime brand – which accounts for 86% of the company’s sales – down 5.4% and the value brand Adimil down 65.7%.
Australian nutraceutical firm Gordagen Pharmaceuticals is preparing to launch its heart health and endurance products in the US by the end of the year.
Implementing stringent safety and quality regulations, tackling micronutrient deficiencies and maximising the opportunities from inward investment need to be three of key priorities for the food industry in India, amid projections of a doubling of production...
Shanghai Pharmaceuticals Holding Co Ltd and private equity firm Primavera Capital is to buy Australian vitamin manufacturer Vitaco Holdings for US$239m.